TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8393760

Group type: EXPERIMENTAL
Intervention: Immunization shots on day 0 and day 14 (n = 47)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Immunization shots on day 0 and day 28 (n = 50)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Immunization shots on day 0, 14 and 28 (n = 47)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: All groups (after booster shot)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: All groups (after first immunization)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: All groups (between second and third immunization)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Three injections two weeks apart
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 144
Study: 30900326

Group type: EXPERIMENTAL
Intervention: High-dose caffeine citrate (80 mg/kg)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Standard-dose caffeine citrate (20 mg/kg)
Number of subjects: 218
Study: 29791275

Group type: EXPERIMENTAL
Intervention: Web-based intervention for advanced care planning
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 26473766

Group type: EXPERIMENTAL
Intervention: Individuals sleeping in public places
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Individuals sleeping in shelters
Number of subjects: 1008
Study: 24709499

Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 60
Study: 22341379

Group type: EXPERIMENTAL
Intervention: Neural tissue management (education, manual therapy, and nerve gliding exercises in 4 treatments over 2 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neural tissue management
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (usual activities advice)
Number of subjects: 60
Study: 20347506

Group type: EXPERIMENTAL
Intervention: gemcitabine 1000 mg/m(2) days 1 and 8 plus carboplatin AUC 5.5 day 1 (GCb)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: gemcitabine 1000 mg/m(2) days 1 and 8 plus paclitaxel 200 mg/m(2) day 1 (GP)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: paclitaxel 225 mg/m(2) plus carboplatin AUC 6.0 day 1 (PCb)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Overall response rate for squamous patients
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Median time to progression for squamous
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Median time to progression for non-squamous
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Histology-by-treatment interaction effect between GCb and PCb
Number of subjects: 1135
Study: 18041238

Group type: EXPERIMENTAL
Intervention: Visian Toric Implantable Collamer Lens (TICL)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 88
Study: 15642068

Group type: EXPERIMENTAL
Intervention: EMD+BG (test)
Number of subjects: 30

Group type: COMPARATOR
Intervention: EMD (control)
Number of subjects: 30
Study: 12360165

Group type: EXPERIMENTAL
Intervention: Nurse case management program (NURS) including individualized lifestyle modification and pharmacologic intervention for 1 year after discharge
Number of subjects: 228

Group type: COMPARATOR
Intervention: Usual care enhanced with feedback on lipids to primary provider and/or cardiologist (EUC)
Number of subjects: 228
Study: 10204826

Group type: EXPERIMENTAL
Intervention: Resistance exercise plus diet (R+D)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard treatment control plus diet (C+D)
Number of subjects: 20
Study: 7539233

Group type: EXPERIMENTAL
Intervention: High-dose danaparoid (intravenous loading dose of 2000 U followed by 2000 U administered subcutaneously twice daily)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Unfractionated heparin (intravenous loading dose of 2500 U followed by dose-adjusted continuous infusion)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: High-dose danaparoid
Number of subjects: 209

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: All groups (low-dose danaparoid, high-dose danaparoid, unfractionated heparin)
Number of subjects: 209
Study: 2138985

Group type: EXPERIMENTAL
Intervention: Topical 2% ketoconazole cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 373942

Group type: EXPERIMENTAL
Intervention: Pirprofen (800 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aspirin (3,600 mg/day)
Number of subjects: 40
Study: 31627938

Group type: EXPERIMENTAL
Intervention: 4 grams/day of a highly purified omega‐3 product containing eicosapentaenoic acid (EPA)
Number of subjects: 8179

Group type: EXPERIMENTAL
Intervention: Approximately 1 gram/day of purified fish oil containing 840 mg/day of EPA and docosahexaenoic acid (DHA)
Number of subjects: 8179
Study: 30766593

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at 0.4mcg/kg/hr
Number of subjects: 104

Group type: COMPARATOR
Intervention: Remifentanil infusion at 0.2mcg/kg/min
Number of subjects: 104
Study: 26867000

Group type: EXPERIMENTAL
Intervention: Subjective stimulant-like effects
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Subjective sedative-like effects
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 23013107

Group type: EXPERIMENTAL
Intervention: Transcranial laser therapy with the NeuroThera® Laser System
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Sham transcranial laser therapy procedure
Number of subjects: 1000
Study: 22777879

Group type: EXPERIMENTAL
Intervention: Various obesity treatments (specific treatments not detailed)
Number of subjects: 191
Study: 20361844

Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pulse oximetry
Number of subjects: 50
Study: 18386721

Group type: COMPARATOR
Intervention: 1% Propofol-LCT
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 1% Propofol-LCT/MCT
Number of subjects: 110
Study: 15909273

Group type: EXPERIMENTAL
Intervention: Concentration-controlled intervention (CCI)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control (no CCI)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Rules-based interpretation (GI)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Virtual phenotype interpretation (VPI)
Number of subjects: 230
Study: 11899591

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.25 mg) administered twice daily to the treated group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 52
Study: 9732095

Group type: EXPERIMENTAL
Intervention: Endometrial ablation
Number of subjects: 800

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 800
Study: 7653806

Group type: EXPERIMENTAL
Intervention: Eltanolone (0.5 mg/kg) + fentanyl (3 micrograms/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thiopental (3 mg/kg) + fentanyl (3 micrograms/kg)
Number of subjects: 50
Study: 2567570

Group type: EXPERIMENTAL
Intervention: Non-ionic contrast medium (iohexol)
Number of subjects: 9
Study: 795564

Group type: EXPERIMENTAL
Intervention: Gonadotrophin releasing hormone (500 mug subcutaneously every 8 h for 4 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30592476

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (1.5 mg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intranasal fentanyl (2 μg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intranasal fentanyl
Number of subjects: 90
Study: 27883311

Group type: EXPERIMENTAL
Intervention: Higher self-efficacy
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: More than 10 male partners in the past 6 months
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Higher optimism regarding the effects of HIV treatments on HIV transmission
Number of subjects: 354
Study: 27100764

Group type: EXPERIMENTAL
Intervention: Rapid testing for Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) diagnosis
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care testing
Number of subjects: 70
Study: 24532685

Group type: EXPERIMENTAL
Intervention: Open Nissen fundoplication (ONF)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 39
Study: 22112293

Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study: 20851560

Group type: EXPERIMENTAL
Intervention: Positive framing (70% effective)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Negative framing (30% ineffective)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control frame
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Mixed valence frames
Number of subjects: 334
Study: 17953496

Group type: EXPERIMENTAL
Intervention: Implementation intentions in the experimental condition
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control condition (no implementation intentions)
Number of subjects: 90
Study: 16425125

Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine plus zidovudine (SD-NVP + ZDV)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Single-dose nevirapine (SD-NVP) alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both regimens (SD-NVP + ZDV and SD-NVP alone)
Number of subjects: 38
Study: 12830834

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (ME)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 10
Study: 10589810

Group type: EXPERIMENTAL
Intervention: Plastic curettes (Universal Perio Soft Scaler)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional steel curettes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Plastic curettes
Number of subjects: 40
Study: 8709689

Group type: COMPARATOR
Intervention: Sting removal by scraping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sting removal by pinching
Number of subjects: 0
Study: 1650036

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) with polymyxin, amphotericin, tobramycin, and intravenous cefotaxime
Number of subjects: 331

Group type: COMPARATOR
Intervention: Standard antibiotic therapy (Control)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 331
Study: 6846940

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31476706

Group type: EXPERIMENTAL
Intervention: Lavender essential oil in the ostomy bag
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine practices about nutrition and stoma care
Number of subjects: 30
Study: 28455894

Group type: EXPERIMENTAL
Intervention: Community Treatment Program (CTP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Individual Treatment Program (ITP)
Number of subjects: 80
Study: 25886615

Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) training course comprising two face to face 6.5 hour sessions run over two days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlisted control group (not receiving MHFA training during the study)
Number of subjects: 100
Study: 23701746

Group type: EXPERIMENTAL
Intervention: AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909)
Number of subjects: 105

Group type: COMPARATOR
Intervention: BioThrax (0.5 mL)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Saline placebo (0.5 mL)
Number of subjects: 105
Study: 21392109

Group type: EXPERIMENTAL
Intervention: Multi-component interventions (class education, free sunscreen samples, written materials)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Written materials only (subgroup B)
Number of subjects: 285
Study: 19962469

Group type: EXPERIMENTAL
Intervention: Optimal medical therapy (OMT)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) plus OMT
Number of subjects: 320

Group type: COMPARATOR
Intervention: CKD patients (both OMT and PCI plus OMT)
Number of subjects: 320
Study: 17364078

Group type: EXPERIMENTAL
Intervention: Psycho-educational interventions (telephone counselling, self-help course, group psychotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapies (Riquent, belimumab, mycophenolate mofetil, dehydroepiandrosterone, oestrogen therapy, cholesterol-lowering diet)
Number of subjects: 0
Study: 15206062

Group type: COMPARATOR
Intervention: scIL-2 at a dose of 1.5 mIU (n=36)
Number of subjects: 218

Group type: COMPARATOR
Intervention: scIL-2 at a dose of 4.5 mIU (n=36)
Number of subjects: 218

Group type: COMPARATOR
Intervention: scIL-2 at a dose of 7.5 mIU (n=37)
Number of subjects: 218
Study: 12394945

Group type: EXPERIMENTAL
Intervention: Early high-volume hemofiltration (72-96 L per 24 hrs)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Early low-volume hemofiltration (24-36 L per 24 hrs)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Late low-volume hemofiltration (24-36 L per 24 hrs)
Number of subjects: 106
Study: 9891536

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy (52 cases)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Radiotherapy alone (14 cases)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Combined modality (50 cases)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Tonsillar NHL (56 cases)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Non-tonsillar NHL (60 cases)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Stage I and II non-tonsillar patients
Number of subjects: 116

Group type: COMPARATOR
Intervention: Tonsillar group
Number of subjects: 116

Group type: COMPARATOR
Intervention: Non-tonsillar group
Number of subjects: 116
Study: 7802176

Group type: EXPERIMENTAL
Intervention: Laryngeal mask (Intavent)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tracheal tube (Rüsch)
Number of subjects: 10
Study: 2919938

Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) with a spacer
Number of subjects: 36

Group type: COMPARATOR
Intervention: Updraft-compressor nebulization (UDN)
Number of subjects: 36
Study: 4571186

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30361758

Group type: EXPERIMENTAL
Intervention: Preoperative high-intensity strength training
Number of subjects: 44
Study: 28296957

Group type: EXPERIMENTAL
Intervention: NAV (navigation system)
Number of subjects: 120

Group type: COMPARATOR
Intervention: CT (conventional procedures)
Number of subjects: 120
Study: 26581079

Group type: EXPERIMENTAL
Intervention: Registered trials
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Trials with adequate outcome analysis definitions
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Trials with multiple primary outcome analyses
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Trials registered prior to patient enrollment
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Discrepancy in registered and published outcomes
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Adequate registration as per guidelines
Number of subjects: 70

Group type: COMPARATOR
Intervention: Comparison with psychosomatic and behavioral medicine journals
Number of subjects: 70

Group type: COMPARATOR
Intervention: Comparison of registered trials
Number of subjects: 70
Study: 24153416

Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Tilt table testing (TT)
Number of subjects: 504
Study: 21237708

Group type: EXPERIMENTAL
Intervention: Soft orthosis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Semi-rigid orthosis
Number of subjects: 40

Group type: COMPARATOR
Intervention: No orthosis (control condition)
Number of subjects: 40
Study: 19484680

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg chewable tablets
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 17698939

Group type: EXPERIMENTAL
Intervention: Adding intermediate measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Design with three repeated measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Design with more than three measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal design based on first-order auto-regressive structure with measurement error
Number of subjects: 0
Study: 15123939

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated prostheses
Number of subjects: 24

Group type: COMPARATOR
Intervention: Noncoated prostheses
Number of subjects: 24
Study: 11549097

Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg (oral capsule or intravenous infusion)
Number of subjects: 10
Study: 9626609

Group type: EXPERIMENTAL
Intervention: $5 cash incentive plus standardized TB education
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standardized TB education alone
Number of subjects: 79
Study: 8142265

Group type: EXPERIMENTAL
Intervention: Treatment B (FT + TAM 20 mg day‐1 for 2 years after DOX administration)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Treatment A (FT 50 mg day‐1 for 2 years after DOX administration)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Treatment B (FT + TAM 20 mg day‐1 for 2 years)
Number of subjects: 512
Study: 2802643

Group type: EXPERIMENTAL
Intervention: bendroflumethiazide (bendrofluazide)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study: 769751

Group type: EXPERIMENTAL
Intervention: Experimental rooms (not cleaned between consecutive clean operations, cleaned after contaminated operations)
Number of subjects: 2020

Group type: COMPARATOR
Intervention: Control rooms (uniformly received Wet‐Vac cleaning between operations)
Number of subjects: 2020
Study: 30707049

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg once daily at bedtime (qhs)
Number of subjects: 2465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2465
Study: 29211803

Group type: EXPERIMENTAL
Intervention: Normoxic bed rest (NBR)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Hypoxic bed rest (HBR)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Hypoxic ambulation (HAmb)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Inactivity combined with hypoxia
Number of subjects: 231
Study: 26356615

Group type: EXPERIMENTAL
Intervention: Cytoflavin (20 ml per day for 10 days)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Cytoflavin (10 ml per day from 11th to 20th day)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Ascorbic acid (control group)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Cytoflavin (20-day therapy)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Cytoflavin (10-day therapy)
Number of subjects: 373
Study: 23496988

Group type: EXPERIMENTAL
Intervention: Improved oral health care and a diet of increased consistency
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 0
Study: 22127965

Group type: EXPERIMENTAL
Intervention: Continuous sequential estrogen plus progestin (n = 52)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (n = 54)
Number of subjects: 106
Study: 19851520

Group type: EXPERIMENTAL
Intervention: Parnaparin (3200, 4250, 6400, or 12800 IUaXa) administered subcutaneously once daily for 3 to 5 days to 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parnaparin
Number of subjects: 0
Study: 17384437

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg once per day (n = 2072)
Number of subjects: 4133

Group type: COMPARATOR
Intervention: Placebo (n = 2061)
Number of subjects: 4133

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg once per day
Number of subjects: 4133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4133
Study: 15282005

Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Abdominal Hysterectomy (AH)
Number of subjects: 30
Study: 10972580

Group type: EXPERIMENTAL
Intervention: 10% dextrose infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 8
Study: 8630518

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH 0.1 IU/kg body wt per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1569442

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (one cycle)
Number of subjects: 1275

Group type: COMPARATOR
Intervention: No adjuvant treatment (control)
Number of subjects: 1275
Study: 6372372

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 31104758

Group type: EXPERIMENTAL
Intervention: Intraoperative rScO2 monitoring
Number of subjects: 153
Study: 29946346

Group type: EXPERIMENTAL
Intervention: Delayed wound closure
Number of subjects: 607

Group type: COMPARATOR
Intervention: Primary wound closure
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Clinical prediction score
Number of subjects: 607
Study: 29231300

Group type: EXPERIMENTAL
Intervention: Combined treatment group (flying needling therapy + clomiphene)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Flying needling therapy group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Medication group (clomiphene)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined treatment group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Medication group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined treatment group and Flying needling therapy group
Number of subjects: 90
Study: 24993832

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 22012708

Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 19460855

Group type: EXPERIMENTAL
Intervention: Transbond XT
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Eagle Bond
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Light Bond
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Blugloo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Unite
Number of subjects: 75